Suppr超能文献

腹腔镜检查用于诊断晚期卵巢癌患者疾病的可切除性。

Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer.

作者信息

Rutten Marianne J, Leeflang Mariska M G, Kenter Gemma G, Mol Ben Willem J, Buist Marrije

机构信息

Department of Obstetrics and Gynaecology, Academic Medical Center, Amsterdam, Netherlands.

出版信息

Cochrane Database Syst Rev. 2014 Feb 21;2014(2):CD009786. doi: 10.1002/14651858.CD009786.pub2.

Abstract

BACKGROUND

The presence of residual tumour after primary debulking surgery is the most important prognostic factor in patients with advanced ovarian cancer. In up to 60% of cases, residual tumour of more than 1 cm is left behind, stressing the necessity of accurately selecting those patients who should be treated with primary debulking surgery and those who should receive neoadjuvant chemotherapy instead.

OBJECTIVES

To determine if performing an open laparoscopy after the diagnostic work-up of patients suspected of advanced ovarian cancer is accurate in predicting the resectability of disease.

SEARCH METHODS

We searched MEDLINE, EMBASE, The Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Register of Diagnostic Test Accuracy Studies, MEDION and ISI Web of Science to February 2013. Furthermore, we checked references of identified primary studies and review articles.

SELECTION CRITERIA

We included studies that evaluated the diagnostic accuracy of laparoscopy to determine the resectability of disease in patients who are suspected of advanced ovarian cancer and planned to receive primary debulking surgery.

DATA COLLECTION AND ANALYSIS

Two review authors assessed the quality of included studies using QUADAS-2 and extracted data on study and patients' characteristics, index test, target condition and reference standard. Data for two-by-two tables were extracted and summarised graphically. Sensitivity and specificity and negative predictive values were calculated.

MAIN RESULTS

We included seven studies reporting on six cohorts. Between 27% to 64% of included patients per study were positive on laparoscopy (too extensive disease to warrant laparotomy) and between 36% to 73% were negative (disease suitable for debulking laparotomy). Only two studies avoided partial verification bias and provided data to calculate sensitivity and specificity, which did not justify meta-analysis. These two studies had a sensitivity of 0.70 (95% confidence interval (CI) 0.57 to 0.82) and 0.71 (95% CI 0.44 to 0.90); however, the specificity of both studies was 1.00 (95% CI 0.90 to 1.00). In these two studies there were no false positives, i.e. no patients for whom laparoscopy indicated that major surgery would not be successful and should be avoided, whereas, in reality the patient could be successfully operated upon. Negative predictive values (NPV), for those patients who were diagnosed with having not too extensive disease correctly identified were 0.75 (95% CI 0.55 to 0.86) and 0.96 (95% CI 0.56 to 0.99) due to a different prevalence. Although the studies did report sufficient data to calculate NPVs, we judged these estimates too heterogeneous to meta-analyse.Three studies described the development or validation of a prediction model with a clear cut-off for test positivity. Sensitivity and specificity of these prediction models were 0.30 to 0.70 and 0.89 to 1.00, respectively. However, one of these studies suffered from partial verification bias.

AUTHORS' CONCLUSIONS: Laparoscopy is a promising test, but the low number of studies and the differences between the included studies do not allow firm conclusions to be drawn from these data. Due to a difference in prevalence, there is a wide range in negative predictive values between studies. Two studies verified all patients. These imply a high specificity of laparoscopy in diagnosing resectability and have a good sensitivity. Both studies show that the use of criteria for unresectable disease will result in no patients inappropriately unexplored. However, there will still be patients undergoing unsuccessful primary laparotomy. Using a prediction model does not increase the sensitivity and will result in more unnecessarily explored patients, due to a lower specificity.

摘要

背景

初次肿瘤细胞减灭术后残留肿瘤的存在是晚期卵巢癌患者最重要的预后因素。在高达60%的病例中,会残留直径超过1 cm的肿瘤,这凸显了准确选择那些应接受初次肿瘤细胞减灭术治疗的患者以及那些应接受新辅助化疗的患者的必要性。

目的

确定对疑似晚期卵巢癌患者进行诊断性检查后实施开放性腹腔镜检查在预测疾病可切除性方面是否准确。

检索方法

我们检索了截至2013年2月的MEDLINE、EMBASE、Cochrane对照试验中心注册库(CENTRAL)、Cochrane诊断试验准确性研究注册库、MEDION和ISI科学网。此外,我们还检查了已识别的原始研究和综述文章的参考文献。

选择标准

我们纳入了评估腹腔镜检查诊断准确性的研究,以确定疑似晚期卵巢癌且计划接受初次肿瘤细胞减灭术患者的疾病可切除性。

数据收集与分析

两位综述作者使用QUADAS-2评估纳入研究的质量,并提取有关研究和患者特征、指标试验、目标疾病和参考标准的数据。提取四格表的数据并以图形方式进行汇总。计算敏感性、特异性和阴性预测值。

主要结果

我们纳入了七项报告六个队列的研究。每项研究中纳入的患者有27%至64%腹腔镜检查呈阳性(疾病范围太广,不适合开腹手术),36%至73%呈阴性(疾病适合减瘤性开腹手术)。只有两项研究避免了部分验证偏倚并提供了计算敏感性和特异性的数据,这不足以进行荟萃分析。这两项研究的敏感性分别为0.70(95%置信区间(CI)0.57至0.82)和0.71(95%CI 0.44至0.90);然而,两项研究的特异性均为1.00(95%CI 0.90至1.00)。在这两项研究中没有假阳性,即没有患者腹腔镜检查显示大手术不会成功且应避免,而实际上患者可以成功进行手术。由于患病率不同,对于那些被正确诊断为疾病范围不太广泛的患者,阴性预测值(NPV)分别为0.75(95%CI 0.55至0.86)和0.96(95%CI 0.56至0.99)。尽管这些研究确实报告了足够的数据来计算NPV,但我们认为这些估计值差异太大,无法进行荟萃分析。三项研究描述了具有明确阳性检测临界值的预测模型的开发或验证。这些预测模型的敏感性和特异性分别为0.30至0.70和0.89至1.00。然而,其中一项研究存在部分验证偏倚。

作者结论

腹腔镜检查是一项有前景的检查,但研究数量较少且纳入研究之间存在差异,无法从这些数据中得出确凿结论。由于患病率不同, 各研究间的阴性预测值范围较宽。两项研究对所有患者进行了验证。这意味着腹腔镜检查诊断可切除性具有较高的特异性且敏感性良好。两项研究均表明, 使用不可切除疾病的标准不会导致任何患者被不恰当地漏诊。然而, 仍会有患者初次开腹手术不成功。使用预测模型不会提高敏感性,且由于特异性较低,会导致更多患者被不必要地进行检查。

相似文献

1
Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer.
Cochrane Database Syst Rev. 2014 Feb 21;2014(2):CD009786. doi: 10.1002/14651858.CD009786.pub2.
2
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
3
Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses.
Cochrane Database Syst Rev. 2016 Mar 1;3(3):CD010360. doi: 10.1002/14651858.CD010360.pub2.
5
Optimal primary surgical treatment for advanced epithelial ovarian cancer.
Cochrane Database Syst Rev. 2011 Aug 10;2011(8):CD007565. doi: 10.1002/14651858.CD007565.pub2.
6
Blood biomarkers for the non-invasive diagnosis of endometriosis.
Cochrane Database Syst Rev. 2016 May 1;2016(5):CD012179. doi: 10.1002/14651858.CD012179.
7
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
8
Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.
Cochrane Database Syst Rev. 2018 Jan 22;1(1):CD011551. doi: 10.1002/14651858.CD011551.pub2.
9
123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.
Cochrane Database Syst Rev. 2015 Sep 29;2015(9):CD009263. doi: 10.1002/14651858.CD009263.pub2.

引用本文的文献

1
Oral CT Contrast Agents: What's New and Why, From the Special Series on Contrast Media.
AJR Am J Roentgenol. 2024 Oct;223(4):e2329970. doi: 10.2214/AJR.23.29970. Epub 2023 Oct 25.
2
Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors.
Int J Mol Sci. 2023 Jun 29;24(13):10859. doi: 10.3390/ijms241310859.
4
Role of diagnostic laparoscopy in deciding primary treatment in advanced-stage ovarian cancer.
J Gynecol Oncol. 2023 Mar;34(2):e17. doi: 10.3802/jgo.2023.34.e17. Epub 2022 Dec 8.
5
The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients.
Cancers (Basel). 2022 Nov 23;14(23):5757. doi: 10.3390/cancers14235757.
6
Laparoscopic Surgery for Ovarian Neoplasms - What is Possible, What is Useful?
Geburtshilfe Frauenheilkd. 2022 Dec 1;82(12):1368-1377. doi: 10.1055/a-1787-9144. eCollection 2022 Dec.
8
MicroRNA characteristics in epithelial ovarian cancer.
PLoS One. 2021 Jun 4;16(6):e0252401. doi: 10.1371/journal.pone.0252401. eCollection 2021.
9
Suprarenal lymphadenectomy with nephrectomy for refractory ovarian cancer.
Gland Surg. 2021 Mar;10(3):1268-1270. doi: 10.21037/gs.2020.04.08.

本文引用的文献

1
Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?
Gynecol Oncol. 2013 Jan;128(1):6-11. doi: 10.1016/j.ygyno.2012.09.013. Epub 2012 Sep 21.
2
Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
Cochrane Database Syst Rev. 2012 Aug 15;2012(8):CD005343. doi: 10.1002/14651858.CD005343.pub3.
4
Cancer statistics, 2012.
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
5
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.
Ann Intern Med. 2011 Oct 18;155(8):529-36. doi: 10.7326/0003-4819-155-8-201110180-00009.
6
Optimal primary surgical treatment for advanced epithelial ovarian cancer.
Cochrane Database Syst Rev. 2011 Aug 10;2011(8):CD007565. doi: 10.1002/14651858.CD007565.pub2.
7
The role of surgery in the management of epithelial ovarian cancer.
Cancer Control. 2011 Jan;18(1):22-30. doi: 10.1177/107327481101800104.
9
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验